Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
CITRIC ACID; MAGNESIUM OXIDE; SODIUM PICOSULFATE vs ORPHENGESIC
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Sodium picosulfate is a stimulant laxative that is hydrolyzed by colonic bacteria to the active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane, which stimulates colonic peristalsis by acting on the colonic mucosa and inhibiting water and electrolyte absorption. Magnesium oxide acts as an osmotic laxative by drawing water into the intestinal lumen. Citric acid reacts with magnesium oxide to form magnesium citrate, an osmotic laxative.
ORPHENGESIC (oxycodone/naloxone) is a combination of an opioid agonist (oxycodone) and an opioid antagonist (naloxone). Oxycodone acts primarily on mu-opioid receptors in the CNS to produce analgesia; naloxone, at oral doses, has low systemic bioavailability but antagonizes opioid effects on gut opioid receptors to reduce constipation.
Bowel cleansing prior to colonoscopy,FDA-approved for bowel preparation in adults
Management of moderate to severe pain requiring around-the-clock opioid therapy in patients who have failed alternative treatments,Opioid-induced constipation (off-label use of combination due to naloxone component)
Adult: 10 mg oral sodium picosulfate (as 10 mg powder for oral solution) plus 3.5 g magnesium oxide and 12 g citric acid, taken as a single dose the day before colonoscopy, followed by a second dose the next morning, for a total of 2 doses.
10 mg oral every 4-6 hours as needed; maximum 60 mg per day.
The terminal elimination half-life of the active metabolite BHPM is approximately 7-9 hours; clinical effect (bowel cleansing) begins within 1-3 hours and is complete by 6 hours.
3-4 hours in adults; prolonged in hepatic impairment (up to 6-8 hours) and elderly (up to 5 hours). Requires dose adjustment in cirrhosis.
Sodium picosulfate is hydrolyzed by colonic bacteria to its active metabolite. Magnesium and citrate are not metabolized; they are absorbed and excreted renally.
Oxycodone is primarily metabolized via CYP3A4 and CYP2D6 to noroxycodone (major) and oxymorphone (minor). Naloxone is extensively metabolized in the liver by UDP-glucuronosyltransferases (UGT2B7) and also by CYP3A4 to naloxone-3-glucuronide.
Sodium picosulfate is primarily excreted in feces (90-95%) as the active metabolite BHPM via biliary elimination; <5% excreted renally. Magnesium oxide is excreted renally as magnesium ions. Citric acid is metabolized to bicarbonate and excreted renally.
Renal: 70-80% as conjugates; fecal: 10-20% via biliary elimination; <5% unchanged drug in urine.
Sodium picosulfate and its active metabolite BHPM are minimally protein bound (<5%); magnesium oxide and citric acid are not significantly protein bound.
90-95% primarily to alpha-1-acid glycoprotein and albumin.
The volume of distribution of the active metabolite BHPM is not well defined; magnesium distributes mainly to extracellular fluid (0.2-0.4 L/kg).
2.5-3.5 L/kg; large Vd indicates extensive tissue distribution, including CNS.
Sodium picosulfate is a prodrug; systemic bioavailability of BHPM after oral administration is approximately 10-15% due to extensive presystemic metabolism.
Oral: 40-60% (first-pass effect); Sublingual: 15-25%; Intramuscular: 70-80%; Rectal: 40-60%; Intravenous: 100%.
Contraindicated in patients with severe renal impairment (e GFR < 30 m L/min/1.73 m²). For e GFR 30-60, use with caution and ensure adequate hydration.
GFR 30-50 m L/min: 5 mg every 6 hours; GFR 15-29 m L/min: 5 mg every 8 hours; GFR <15 m L/min: 5 mg every 12 hours; avoid in dialysis.
No specific adjustment provided; use with caution in severe hepatic impairment (Child-Pugh C) due to potential for electrolyte disturbances.
Child-Pugh A: 5 mg every 6 hours; Child-Pugh B: 5 mg every 8 hours; Child-Pugh C: not recommended.
Safety and efficacy not established in pediatric patients; not recommended for use in children.
6-12 years: 0.5 mg/kg oral every 6 hours; 12-18 years: 5-10 mg oral every 6 hours; maximum 60 mg/day.
No specific dose adjustment; ensure adequate hydration and monitor electrolyte levels due to increased risk of renal impairment and dehydration.
Initiate at 5 mg oral every 6 hours; titrate cautiously due to increased sensitivity and risk of falls; maximum 30 mg per day.
Risk of acute phosphate nephropathy and renal failure, particularly in patients at increased risk (e.g., renal impairment, dehydration, medications affecting renal function).
WARNING: ADDICTION, ABUSE, AND MISUSE; LIFE-THREATENING RESPIRATORY DEPRESSION; ACCIDENTAL INGESTION; NEONATAL OPIOID WITHDRAWAL SYNDROME; RISKS FROM CONCOMITANT USE WITH BENZODIAZEPINES OR OTHER CNS DEPRESSANTS; and RISKS OF TREATMENT FOR OPIOID USE DISORDER (if applicable).
Do not use in patients with gastrointestinal obstruction, perforation, or ileus.,Use caution in patients with renal impairment, electrolyte abnormalities, or those taking medications that affect electrolyte balance.,Monitor for fluid and electrolyte disturbances.,Avoid use in patients with known hypersensitivity to any component.
Risk of addiction, abuse, and misuse,Life-threatening respiratory depression,Accidental ingestion (especially in children),Neonatal opioid withdrawal syndrome,Risks from concomitant use of benzodiazepines or other CNS depressants,Adrenal insufficiency,Severe hypotension,Seizures,Chronic use may cause physical dependence and withdrawal if abruptly discontinued
Gastrointestinal obstruction, ileus, or perforation,Renal failure (creatinine clearance < 30 m L/min),Ascites,Congestive heart failure (NYHA class III or IV),Known hypersensitivity to any component
Hypersensitivity to oxycodone, naloxone, or any component,Significant respiratory depression,Acute or severe bronchial asthma in an unmonitored setting or without resuscitative equipment,Known or suspected gastrointestinal obstruction, including paralytic ileus,Concomitant use of monoamine oxidase inhibitors (MAOIs) or within 14 days of such therapy
Avoid solid food during bowel preparation. Consume only clear liquids (water, clear broth, apple juice, clear gelatin, black coffee or tea without milk, sports drinks). Avoid red, purple, or orange liquids that can be mistaken for blood during colonoscopy. Do not consume alcohol or dairy products.
Avoid alcohol. No specific food restrictions, but high-fat meals may delay absorption.
No adequate studies in pregnant women. In animal studies, sodium picosulfate showed no teratogenic effects at clinically relevant doses. Theoretical risk of electrolyte disturbances from magnesium absorption may affect fetal development; avoid in first trimester if possible. Insufficient data for second and third trimesters; use only if clearly needed.
Orphengesic (orphenadrine citrate, aspirin, and caffeine) is contraindicated in pregnancy, especially during the third trimester, due to aspirin's association with premature closure of the ductus arteriosus, oligohydramnios, and increased risk of fetal intracranial hemorrhage. First trimester aspirin exposure may increase risk of gastroschisis and other malformations. Orphenadrine has limited data but anticholinergic effects could potentially cause fetal tachycardia or meconium ileus. Caffeine at high doses is associated with low birth weight and miscarriage.
Unknown if components excreted in human milk. Sodium picosulfate may be excreted in small amounts; magnesium and citrate are normal milk constituents. Risk to infant considered low with single doses, but caution advised with chronic use. M/P ratio not available.
Orphengesic is not recommended during breastfeeding. Aspirin excretes into breast milk and may cause Reye's syndrome or platelet dysfunction in the infant. Orphenadrine is excreted in small amounts; its anticholinergic effects may reduce milk production or cause infant sedation. Caffeine levels in milk are low but may cause irritability. M/P ratio for aspirin is ~0.6; data for orphenadrine and caffeine are insufficient.
No pharmacokinetic studies in pregnancy suggest dose adjustment. Use lowest effective dose and shortest duration. Avoid chronic use due to risk of electrolyte imbalances. Single-dose bowel preparation typical; no adjustment recommended.
No established safe dose in pregnancy; use is contraindicated. Physiological changes (increased plasma volume, renal clearance) do not permit safe dosing due to teratogenicity. If unavoidable, lowest effective dose and shortest duration, but aspirin should be <100 mg/day; orphenadrine and caffeine avoid.
Ensure adequate hydration to prevent electrolyte disturbances. Monitor renal function and serum electrolytes, especially in elderly or patients with renal impairment. Administer as a split-dose regimen for optimal bowel cleansing. Avoid use in patients with gastrointestinal obstruction, perforation, or severe inflammatory bowel disease.
ORPHENGESIC contains orphenadrine, a centrally acting muscle relaxant with anticholinergic properties. Avoid in patients with glaucoma, urinary retention, or myasthenia gravis. Onset within 1 hour; monitor for sedation and anticholinergic effects. Not recommended in elderly due to fall risk.
Take this medication exactly as prescribed to prepare your colon for a procedure.,Drink plenty of clear liquids before, during, and after taking this medication to prevent dehydration.,You may experience bloating, cramping, or nausea; these are common and usually resolve after the bowel movement begins.,Do not take any other laxatives or stool softeners while using this product unless directed by your doctor.,Stop taking and contact your doctor if you experience severe abdominal pain, vomiting, or signs of an allergic reaction (rash, itching, swelling).,This medication will cause frequent, watery bowel movements; stay near a bathroom.
May cause drowsiness or dizziness; avoid driving or operating heavy machinery.,Avoid alcohol and other CNS depressants.,Report blurred vision, difficulty urinating, or rapid heartbeat to your doctor.,Swallow tablets whole; do not crush or chew.
"Amphetamine increases renal tubular pH, which reduces the excretion rate of magnesium oxide, potentially leading to elevated serum magnesium levels. This interaction may result in hypermagnesemia, manifesting as hypotension, respiratory depression, or cardiac arrhythmias, particularly in patients with renal impairment."
"Mesoridazine, a phenothiazine antipsychotic, can chelate with magnesium ions in the gastrointestinal tract, forming insoluble complexes that reduce the absorption of magnesium oxide. This leads to diminished serum magnesium concentrations, potentially compromising magnesium's therapeutic effects for conditions such as hypomagnesemia or constipation. Clinically, patients may experience inadequate magnesium supplementation, risking exacerbation of electrolyte imbalances or reduced efficacy of magnesium-based therapies."
"Coadministration of magnesium oxide with rosuvastatin may decrease the serum concentration of rosuvastatin, potentially reducing its cholesterol-lowering efficacy. This interaction is thought to be due to chelation of the statin by magnesium ions in the gastrointestinal tract, impairing absorption. Clinically, this may lead to suboptimal lipid control and increased cardiovascular risk."
No interactions on record
Common clinical questions about CITRIC ACID; MAGNESIUM OXIDE; SODIUM PICOSULFATE vs ORPHENGESIC, answered by our medical review team.
CITRIC ACID; MAGNESIUM OXIDE; SODIUM PICOSULFATE is a Laxative (Osmotic/Stimulant Combination) that works by Sodium picosulfate is a stimulant laxative that is hydrolyzed by colonic bacteria to the active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane, which stimulates colonic peristalsis by acting on the colonic mucosa and inhibiting water and electrolyte absorption. Magnesium oxide acts as an osmotic laxative by drawing water into the intestinal lumen. Citric acid reacts with magnesium oxide to form magnesium citrate, an osmotic laxative.. ORPHENGESIC is a Muscle relaxant combination that works by ORPHENGESIC (oxycodone/naloxone) is a combination of an opioid agonist (oxycodone) and an opioid antagonist (naloxone). Oxycodone acts primarily on mu-opioid receptors in the CNS to produce analgesia; naloxone, at oral doses, has low systemic bioavailability but antagonizes opioid effects on gut opioid receptors to reduce constipation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between CITRIC ACID; MAGNESIUM OXIDE; SODIUM PICOSULFATE and ORPHENGESIC depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of CITRIC ACID; MAGNESIUM OXIDE; SODIUM PICOSULFATE is: Adult: 10 mg oral sodium picosulfate (as 10 mg powder for oral solution) plus 3.5 g magnesium oxide and 12 g citric acid, taken as a single dose the day before colonoscopy, followed by a second dose the next morning, for a total of 2 doses.. The standard adult dose of ORPHENGESIC is: 10 mg oral every 4-6 hours as needed; maximum 60 mg per day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between CITRIC ACID; MAGNESIUM OXIDE; SODIUM PICOSULFATE and ORPHENGESIC in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. CITRIC ACID; MAGNESIUM OXIDE; SODIUM PICOSULFATE is classified as Category C. No adequate studies in pregnant women. In animal studies, sodium picosulfate showed no teratogenic effects at clinically relevant doses. Theoretical risk of electrolyte disturbance. ORPHENGESIC is classified as Category C. Orphengesic (orphenadrine citrate, aspirin, and caffeine) is contraindicated in pregnancy, especially during the third trimester, due to aspirin's association with premature closur. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.